Skip to main
OABI
OABI logo

OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb Inc (OABI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OmniAb Inc. has demonstrated strong financial performance with first-quarter 2025 revenues of $4.2 million, reflecting a 9% increase year-over-year, coupled with a reduction in net losses to $18.2 million, equating to a loss of $0.17 per share, down from $19.0 million, or $0.19 per share the previous year. The company maintains a solid balance sheet which supports its ongoing operations and strategic initiatives. Additionally, the anticipated near- and long-term R&D catalysts are expected to drive further growth and momentum for OmniAb's shares going forward.

Bears say

OmniAb Inc has experienced a decline in its stock price since the November 2022 merger with Avista Public Acquisition Corporation II, primarily due to adverse market conditions affecting similar transactions and established biotechnology firms. The company has indicated expectations for operating cash burn this year to be lower than that of 2024, yet such guidance raises concerns regarding financial sustainability in the context of ongoing operational costs. Overall, the combination of negative market sentiment and potentially high cash burn rates contributes to a fundamentally negative outlook for OmniAb's stock.

OmniAb Inc (OABI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OmniAb Inc (OABI) Forecast

Analysts have given OmniAb Inc (OABI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, OmniAb Inc (OABI) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OmniAb Inc (OABI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.